Eyenovia (NASDAQ:EYEN) Earns “Neutral” Rating from LADENBURG THALM/SH SH

LADENBURG THALM/SH SH reissued their neutral rating on shares of Eyenovia (NASDAQ:EYEN) in a research note published on Monday,Benzinga reports.

Several other brokerages have also recently weighed in on EYEN. William Blair reaffirmed a “market perform” rating on shares of Eyenovia in a research report on Friday. Brookline Capital Management reissued a “hold” rating on shares of Eyenovia in a research report on Friday. Finally, HC Wainwright cut shares of Eyenovia from a “buy” rating to a “neutral” rating and decreased their target price for the company from $12.00 to $2.00 in a research report on Monday.

Eyenovia Price Performance

Eyenovia stock opened at $0.11 on Monday. The stock has a market cap of $7.11 million, a price-to-earnings ratio of -0.15 and a beta of 1.75. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.74 and a quick ratio of 0.27. Eyenovia has a 1 year low of $0.09 and a 1 year high of $2.57. The firm has a 50-day moving average of $0.48 and a two-hundred day moving average of $0.70.

Eyenovia (NASDAQ:EYEN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.02. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%. During the same period in the previous year, the firm posted ($0.18) earnings per share. On average, research analysts forecast that Eyenovia will post -0.5 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Michael M. Rowe purchased 50,000 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was acquired at an average price of $0.57 per share, with a total value of $28,500.00. Following the completion of the acquisition, the chief executive officer now owns 82,927 shares in the company, valued at approximately $47,268.39. This represents a 151.85 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 7.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Armistice Capital LLC acquired a new stake in Eyenovia during the second quarter valued at $3,601,000. Vanguard Group Inc. grew its position in Eyenovia by 25.2% during the first quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock valued at $1,765,000 after buying an additional 360,924 shares during the period. BNP Paribas Financial Markets grew its position in Eyenovia by 1,444.4% during the first quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company’s stock valued at $217,000 after buying an additional 205,390 shares during the period. Geode Capital Management LLC grew its position in Eyenovia by 36.6% during the third quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock valued at $288,000 after buying an additional 149,471 shares during the period. Finally, SkyView Investment Advisors LLC acquired a new stake in Eyenovia during the second quarter valued at $87,000. Hedge funds and other institutional investors own 25.84% of the company’s stock.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.